![[del.icio.us]](http://pennystockdd.com/wp-content/plugins/bookmarkify/delicious.png)
![[Digg]](http://pennystockdd.com/wp-content/plugins/bookmarkify/digg.png)
![[Faves]](http://pennystockdd.com/wp-content/plugins/bookmarkify/faves.png)
![[LinkedIn]](http://pennystockdd.com/wp-content/plugins/bookmarkify/linkedin.png)
![[Reddit]](http://pennystockdd.com/wp-content/plugins/bookmarkify/reddit.png)
![[StumbleUpon]](http://pennystockdd.com/wp-content/plugins/bookmarkify/stumbleupon.png)
![[Technorati]](http://pennystockdd.com/wp-content/plugins/bookmarkify/technorati.png)
| Ticker Symbol: | AVII | ||
| Exchange: | NASDAQ | ||
| Contact Info: | One SW Columbia Street Portland OR 97258 503 227-0554 |
||
| CEO / President: | Leslie Hudson Ph.D. | ||
| Industry/Sector: | Medical – Biomedical | ||
| SIC Code: | SIC-2834 Pharmaceutical Preparations | ||
| Description: | AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI’s lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI’s antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI’s NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy. | ||
Regards,
Don
More on this topic
(What's this?)
Day Trader's Alert: PAR, DTPI, AVII
(Stock Wizard, 8/24/10)
Day Trader's Alert: EPCT, CPIX, AVII
(Stock Wizard, 8/23/10)
AVI BioPharma's Investigational Drug Candidate AVI-4658 Demonstrates Favorable Results
(Benzinga, 10/15/10)
Benzinga's Top Pre-Market NASDAQ Gainers (QCOM, AVII, YRCW, MU)
(Benzinga, 11/4/10)
